Corbacho Belen, Bell Kerry, Stamuli Eugena, Richardson Gerry, Ronaldson Sarah, Hood Kerenza, Sanders Julia, Robling Michael, Torgerson David
York Trials Unit, Department of Health Sciences, University of York, York, UK.
Centre for Health Economics, University of York, York, UK.
J Eval Clin Pract. 2017 Dec;23(6):1367-1374. doi: 10.1111/jep.12799. Epub 2017 Aug 11.
RATIONAL, AIMS, AND OBJECTIVES: The Family Nurse Partnership (FNP) is a licensed intensive home visiting intervention developed in the United States. It has been provided in England by the Department of Health since 2006. The Building Blocks trial assessed the effectiveness and cost-effectiveness of FNP in England.
We performed a cost-utility analysis (National Health Service (NHS) perspective) alongside the Building Blocks trial (over 2.5 y). The analysis was conducted in accordance with National Institute for Health and Clinical Excellence (NICE) reference case standards. Health-related quality of life was elicited from mothers using the EQ-5D-3L. Resource-use data were collected from self-reported questionnaires, Hospital Episode Statistics, general practitioner records and the central Department of Health FNP database. Costs and quality-adjusted life years (QALYs) were discounted at 3.5%. The base case analysis used an intention to treat approach on the imputed dataset using multiple imputation.
The FNP intervention costs on average £1812 more per participant compared to usual care (95% confidence interval: -£2700; £5744). Incremental adjusted mean QALYs are marginally higher for FNP (mean difference 0.0036, 95% confidence interval: -0.017; 0.025). The probability of FNP being cost-effective is less than 20% given the current NICE willingness to pay threshold of £20 000 per additional QALY. The results were robust to sensitivity analyses.
Given the absence of significant benefits of FNP in terms of the primary outcomes of the trial and only marginal maternal QALY gains, FNP does not represent a cost-effective intervention when compared with existing services already offered to young pregnant women.
原理、目的和目标:家庭护士伙伴关系(FNP)是在美国开发的一项获得许可的强化家庭访视干预措施。自2006年以来,英国卫生部一直在提供该服务。“基石”试验评估了FNP在英国的有效性和成本效益。
我们在“基石”试验(超过2.5年)的同时进行了成本效用分析(从英国国家医疗服务体系(NHS)的角度)。该分析是根据英国国家卫生与临床优化研究所(NICE)的参考案例标准进行的。使用EQ-5D-3L从母亲那里获取与健康相关的生活质量数据。资源使用数据从自我报告问卷、医院 Episode 统计数据、全科医生记录以及卫生部中央FNP数据库中收集。成本和质量调整生命年(QALYs)按3.5%进行贴现。基础案例分析在使用多重插补的估算数据集上采用意向性分析方法。
与常规护理相比,FNP干预每位参与者的平均成本高出1812英镑(95%置信区间:-2700英镑;5744英镑)。FNP的增量调整后平均QALYs略高(平均差异0.0036,95%置信区间:-0.017;0.025)。鉴于目前NICE每增加一个QALY支付意愿阈值为20000英镑,FNP具有成本效益的概率小于20%。结果对敏感性分析具有稳健性。
鉴于FNP在试验的主要结局方面没有显著益处,且仅使母亲的QALY略有增加,与已经提供给年轻孕妇的现有服务相比,FNP不代表一种具有成本效益的干预措施。